Breakthrough dementia drugs 'will be useless for 80 per cent' warn top British experts Donanemab and lecanemab are both expected to be approved for NHS use READ MORE: Study shows erectile dysfunction drug may help ward off dementia By Emily Stearn, Health Reporter For Mailonline and Kate Pickles Health Editor For The Daily Mail Published: 17:01, 12 June 2024 | Updated: 17:31, 12 June 2024 e-mail 6 View comments More than 80 per cent of Brits at risk of Alzheimer's could miss out on revolutionary new drugs to treat the incurable disease, experts warned today. Donanemab and lecanemab have both been proven to slow the progress of the memory-robbing illness in its early stages. They are expected to be approved for NHS use later this year, with each already given the green light in the US.
But a lack of proper Alzheimer's testing at scale means the health service risks being 'overwhelmed' by the demand for two new drugs, researchers argued. Instead, the scientists from London estimated just 14 per cent of patients referred to clinics were actually likely to benefit from the treatments. Donanemab and lecanemab (pictured), have both been proven to slow the progress of the memory-robbing illness in its early stages.
They are expected to be approved for NHS use later this year, with each already given the green light in the US The two drugs have been proven to slow progression of the disease by as much as 60 per cent in trials by helping to remove the build up of the protein amyloid i.
